Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan

NCT02042014 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Pulmonary Arterial Hypertension

Interventions

DRUG: QTI571

Sponsor

Novartis Pharmaceuticals